Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,618,913

« Back to Dashboard

Summary for Patent: 5,618,913

Title: Insulin analogues
Abstract:Novel rapid-acting human insulin analogues are provided having less tendency to self-association into dimers, tetramers, hexamers, or polymers. The novel human insulin analogues are formed by substituting one or more of the amino acid residues of human insulin with naturally occuring amino acid residues. The amino acid residue substitutions are preferably more hydrophilic than the natural amino acid residue at the respective position in the molecule. Furthermore, the insulin analogues have the same charge or a greater negative charge at neutral pH than that of human insulin. Preferred amino acid substitutions are Asp, Glu, Ser, Thr, His, and Ile, and more preferred substitutions are Asp and Glu. The novel insulin analogues can be used for the preparation of rapid-acting insulin solutions.
Inventor(s): Brange; Jens J. V. (Klampenborg, DK), Norris; Kjeld (Hellerup, DK), Hansen; Mogens T. (Lynge, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:06/901,821
Patent Claim Types:
see list of patent claims
Compound; Formulation;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,618,913

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark3956/85Aug 30, 1985
Denmark4677/85Oct 14, 1985

International Patent Family for Patent: 5,618,913

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina241801<disabled in preview>
Austria113061<disabled in preview>
Australia593274<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.